Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.38 |
| ▸ | PDE2A | O00408 | 8/20 | 0.36 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.34 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.34 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 2/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8768349 | 0.99 | EPHX2 (0.39) | S1PR1EPHX2PDE2AFFAR4HCRTR1 | |
| SCHEMBL12997536 | 0.89 | EPHX2 (0.45) | EPHX2PDE2AKDM1A | |
| SCHEMBL8767847 | 0.89 | PDE2A (0.36) | S1PR1EPHX2PDE2AHCRTR1HCRTR2 | |
| SCHEMBL8767553 | 0.88 | S1PR1 (0.34) | S1PR1EPHX2PDE2AFFAR4HCRTR1 | |
| SCHEMBL8767562 | 0.88 | S1PR1 (0.34) | S1PR1EPHX2PDE2AFFAR4HCRTR1 | |
| SCHEMBL8767544 | 0.88 | S1PR1 (0.34) | S1PR1EPHX2PDE2AFFAR4HCRTR1 | |
| SCHEMBL10001732 | 0.87 | ESR2 (0.38) | EPHX2PDE2AFFAR4HCRTR1HCRTR2 | |
| SCHEMBL13345610 | 0.87 | EPHX2 (0.38) | EPHX2PDE2AFFAR4KDM1A | |
| SCHEMBL19606422 | 0.87 | S1PR1 (0.37) | S1PR1EPHX2PDE2AFFAR4 | |
| SCHEMBL8767623 | 0.84 | PDE2A (0.38) | S1PR1EPHX2PDE2AHCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230068853-A1 | LIQUID CRYSTAL MIXTURE AND LIQUID CRYSTAL DISPLAY | MERCK PATENT GMBH (DE) | 2023-03-02 | — | — | US | disclosed |
| US-20230053362-A1 | DICHROIC DYE COMPOSITION | MERCK PATENT GMBH (DE) | 2023-02-23 | — | — | US | disclosed |
| US-20230056437-A1 | AZO DYE | MERCK PATENT GMBH (DE) | 2023-02-23 | — | — | US | disclosed |
| US-11168257-B2 | Liquid crystalline medium | MERCK PATENT GMBH (DE) | 2021-11-09 | — | — | US | disclosed |
| US-11060029-B2 | Liquid-crystalline medium and liquid-crystal display comprising the same | MERCK PATENT GMBH (DE) | 2021-07-13 | — | — | US | disclosed |
| US-10982149-B2 | Chiral compounds | MERCK PATENT GMBH (DE) | 2021-04-20 | — | — | US | disclosed |
| US-10738243-B2 | Liquid-crystalline medium and liquid-crystal display | MERCK PATENT GMBH (DE) | 2020-08-11 | — | — | US | disclosed |
| US-20190153320-A1 | LIQUID CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2019-05-23 | — | — | US | disclosed |
| US-20190127642-A1 | COMPOSITION FOR NANOENCAPSULATION AND NANOCAPSULES COMPRISING A LIQUID-CRYSTALLINE MEDIUM | MERCK PATENT GMBH (DE) | 2019-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10982149-B2 | Chiral compounds | FANCI, COL1A1, LCP1 | S1PR1 3616/4885EPHX2 1479/4885PDE2A 1221/4885 |
| US-20230068853-A1 | LIQUID CRYSTAL MIXTURE AND LIQUID CRYSTAL DISPLAY | CXCR1, PYM1, F11 | S1PR1 420/4885EPHX2 3517/4885PDE2A 4447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.